Samsung Biologics invests in new plant to expand Bio Campus
Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties.
Samsung Biologics, the leading biotech CDMO, has announced that they will be opening a fifth biomanufacturing plant, not far from their existing Songdo site. The expansion comes in response to increased market demand for biopharmaceuticals.
The building of the 96,000 m2 plant is set to commence this year, with a view to be operational come 2025. It will be the first facility to run under their Bio Campus initiative. The plant will have a capacity of 180,000 litres, bringing Samsung Biologic’s global biomanufacturing capacity to 784,000 litres.
“Given the continuing increase in the demand for outsourced manufacturing of biopharmaceuticals, we are proactively making this investment in alignment with our growth strategy to further strengthen our standing as a leading CDMO,” stated John Rim, President and CEO of Samsung Biologics. “The new facility will enable us to provide our customers with even greater innovation and services that will increase speed to market and flexibility.”
Samsung Biologics are expecting the plant to increase their operational output and efficiency by building on their already acquired expertise, and the technology they have honed through the years in their previous plants. This plant will take this experience one step further with increased use of digitalised technologies and the inclusion of important sustainability-led features.
The second Bio Campus, on which the plant will be based, will also be home to further operational plants and an innovation hub. The campus will cover 360,000 m2 of land and will bear the fruits of a KRW 7.5 trillion investment.
The company’s existing plants are nearly fully functional, with the latest, plant 4, due to be fully operational by the middle of this year.
To further streamline their operations and support their expansion into the US, Samsung Biologics are opening an office in New Jersey, USA in April.
“Our increased US presence will allow us to provide support for clients with even greater agility and engage the broader biotech industry more than ever,” commented Rim.
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance